Sprint Bioscience AB(DE:5JA1)
€0.340.00 (0.00%)
DE:5JA1
Sprint Bioscience AB financials statements
€0.34
At close:0.00 (0.00%)
Sprint Bioscience AB (5JA1) Ratios
0 Followers
Sprint Bioscience AB Ratios
DE:5JA1's free cash flow for Q3 2026 was kr-15.74M. For the 2026 fiscal year, DE:5JA1's free cash flow was decreased by kr-386.00K and operating cash flow was kr-15.36M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.60 | 1.14 | 1.67 | 3.78 | 8.75 |
| Quick Ratio | 7.60 | 1.14 | 1.67 | 3.78 | 8.75 |
| Cash Ratio | 7.25 | 0.76 | 1.44 | 3.19 | 8.14 |
| Solvency Ratio | 5.31 | -0.53 | 0.00 | -6.45 | -2.85 |
| Operating Cash Flow Ratio | 4.78 | -0.71 | 0.66 | -6.40 | -4.62 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | kr 115.39M | kr 4.46M | kr 23.27M | kr 25.65M | kr 67.25M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.15 | 4.54 | 2.25 | 1.33 | 1.12 |
| Debt Service Coverage Ratio | 15.85 | -432.98 | 0.00 | 0.00 | -92.05 |
| Interest Coverage Ratio | 15.68 | -491.70 | 0.00 | 0.00 | -94.67 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.07 | 0.00 | 0.00 | 0.00 | 0.01 |
| Net Debt to EBITDA | -1.29 | 1.45 | -126.10 | 0.49 | 2.88 |
| Profitability Margins | |||||
| Gross Profit Margin | 58.22% | 56.83% | 82.77% | -73384.34% | 70.28% |
| EBIT Margin | 58.22% | -27.78% | -0.10% | -73031.33% | -71.43% |
| EBITDA Margin | 58.86% | -26.38% | 0.78% | -72286.75% | -69.75% |
| Operating Profit Margin | 58.22% | -29.96% | -1.67% | -73384.34% | -72.52% |
| Pretax Profit Margin | 54.88% | -27.84% | -0.87% | -72493.98% | -71.43% |
| Net Profit Margin | 54.88% | -27.84% | -0.87% | -72493.98% | -72.20% |
| Continuous Operations Profit Margin | 54.88% | -27.84% | -0.87% | -72493.98% | -71.43% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 101.07% |
| EBT Per EBIT | 94.25% | 92.93% | 51.83% | 98.79% | 98.50% |
| Return on Assets (ROA) | 67.13% | -43.46% | -0.70% | -160.79% | -32.04% |
| Return on Equity (ROE) | 76.97% | -197.12% | -1.58% | -213.46% | -35.98% |
| Return on Capital Employed (ROCE) | 81.67% | -212.12% | -3.04% | -216.08% | -36.15% |
| Return on Invested Capital (ROIC) | 81.67% | -212.12% | -3.04% | -216.08% | -36.15% |
| Return on Tangible Assets | 67.13% | -43.46% | -0.70% | -160.79% | -32.04% |
| Earnings Yield | 67.39% | -16.78% | -0.37% | -263.06% | -15.50% |
| Efficiency Ratios | |||||
| Receivables Turnover | 27.12 | 5.39 | 62.95 | 0.02 | 11.74 |
| Payables Turnover | 15.87 | 5.21 | 1.52 | 16.37 | 3.57 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -60992.00 | 0.00 |
| Fixed Asset Turnover | 44.73 | 13.92 | 11.53 | 0.04 | 11.75 |
| Asset Turnover | 1.22 | 1.56 | 0.81 | 0.00 | 0.44 |
| Working Capital Turnover Ratio | 2.79 | 4.73 | 2.06 | 0.00 | 0.93 |
| Cash Conversion Cycle | -9.55 | -2.33 | -233.60 | 14823.97 | -71.15 |
| Days of Sales Outstanding | 13.46 | 67.77 | 5.80 | 14846.27 | 31.08 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Days of Payables Outstanding | 23.01 | 70.10 | 239.40 | 22.29 | 102.23 |
| Operating Cycle | 13.46 | 67.77 | 5.80 | 14846.26 | 31.08 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.90 | -0.33 | 0.33 | -1.40 | -1.16 |
| Free Cash Flow Per Share | 0.90 | -0.35 | 0.29 | -1.40 | -1.24 |
| Dividend Paid and CapEx Coverage Ratio | 888.64 | -18.01 | 9.32 | 0.00 | -14.82 |
| Capital Expenditure Coverage Ratio | 888.64 | -18.01 | 9.32 | 0.00 | -14.82 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.50 | -0.36 | 0.45 | -711.49 | -1.14 |
| Free Cash Flow Yield | 61.29% | -22.63% | 17.10% | -258.18% | -26.18% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 1.48 | -6.00 | -272.54 | -0.38 | -6.45 |
| Price-to-Sales (P/S) Ratio | 0.81 | 1.66 | 2.36 | 275.58 | 4.66 |
| Price-to-Book (P/B) Ratio | 1.14 | 11.75 | 4.30 | 0.81 | 2.32 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 1.63 | -4.42 | 5.85 | -0.39 | -3.82 |
| Price-to-Operating Cash Flow Ratio | 1.63 | -4.66 | 5.22 | -0.39 | -4.08 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | -0.00 | 2.74 | -0.00 | 0.10 |
| Enterprise Value Multiple | 0.10 | -4.84 | 175.36 | 0.11 | -3.79 |
| Enterprise Value | 9.43M | 83.86M | 69.44M | -6.62M | 92.92M |
| EV to EBITDA | 0.10 | -4.84 | 175.36 | 0.11 | -3.79 |
| EV to Sales | 0.06 | 1.28 | 1.38 | -79.76 | 2.65 |
| EV to Free Cash Flow | 0.11 | -3.40 | 3.40 | 0.11 | -2.17 |
| EV to Operating Cash Flow | 0.11 | -3.59 | 3.04 | 0.11 | -2.32 |
| Tangible Book Value Per Share | 1.29 | 0.13 | 0.40 | 0.67 | 2.03 |
| Shareholders’ Equity Per Share | 1.29 | 0.13 | 0.40 | 0.67 | 2.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Revenue Per Share | 1.81 | 0.94 | 0.72 | 0.00 | 1.01 |
| Net Income Per Share | 0.99 | -0.26 | -0.01 | -1.43 | -0.73 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.01 |
| Interest Burden | 0.94 | 1.00 | 8.59 | 0.99 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.86 | 0.00 | 0.00 | 0.63 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.91 | 1.19 | -52.22 | 0.98 | 1.57 |
Currency in SEK

